Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast
Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast
复制标题
DOI：
10.1177/172460080401900309
复制
发表时间：
2004-07-01
影响因子：
2
通讯作者：
Koelbl, H
中科院分区：
文献类型：
--
作者：
Lebrecht, A;Grimm, C;Koelbl, H
转化生长因子-β1被认为与乳腺癌的发生有关。转化生长因子-β1在乳腺癌发生的早期阶段起抑制增殖的作用，但在疾病的晚期促进肿瘤的进展和转移。目前还没有关于乳腺癌患者血清转化生长因子-β1的数据发表。我们检测了135例乳腺癌、67例导管原位癌(DCIS)I~III期、35例纤维腺瘤患者和40例健康女性血清中转化生长因子-β1的水平，以确定其作为鉴别恶性、侵袭前疾病和良性疾病的价值以及作为转移转移的预测标志。乳腺癌、DCIS I-III或乳腺良性病变患者及健康女性血清转化生长因子-β1的中位数分别为48.8(18-82.4)、45.3(26.9-58.3)、47.2(17.2-80.5)、51.6(30.9-65.1)pg/mL(P=0.2)。乳腺癌患者血清转化生长因子-β1水平与肿瘤分期、淋巴结转移、组织学分级、雌激素受体状态和孕激素受体状态无统计学意义相关。我们的数据没有表明血清转化生长因子-β1水平与乳腺疾病的临床病理参数之间有任何相关性。除了已建立的肿瘤标志物外，血清转化生长因子-β1水平不能提供临床信息。
Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an anti proliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 serum levels in patients with breast cancer, DCIS I-III or benign breast lesions and in healthy women were 48.8 (18-82.4) pg/mL, 45.3 (26.9-58.3) pg/mL, 47.2 (17.2-80.5) pg/mL and 51.6 (30.9-65.1) pg/mL, respectively (p=0.2). In breast cancer patients TGF-beta1 serum levels showed no statistically significant correlation with tumor stage, lymph node involvement, histological grade, estrogen receptor status and progesterone receptor status. Our data fail to indicate any correlation between serum TGF-beta1 levels and clinicopathological parameters of breast diseases. Serum TGF-beta1 levels do not provide clinical information in addition to established tumor markers.